Skip to main content
Policy & Funding· Daily Pulse

Washington Is Betting $20 Million on Ketamine as a Cure. People It Has Hurt Are Still Being Sent Home With Painkillers.

NIMH's new rapid-acting treatment network is a real step for psychiatry. A survey of 274 people with ketamine use disorder shows the other half of the story nobody funded.

ByThe Rize NewsroomNovember 15, 20262 min readDissociatives

“I attended A&E with my bladder feeling like it was about to burst but no urine was coming out for 5 and a half hours,” one person told researchers. Another: “All they did was give me painkillers and send me on my way.” A third said their family doctor “does not think ketamine is addictive, just told me to stop.” Those are three of 274 people with ketamine use disorder surveyed by Rebecca Harding, Celia Morgan and colleagues at the University of Exeter and University College London, published in Addiction in 2025.

On Thursday, the federal government announced its biggest ketamine bet yet, and it was not for them.

We are funding the cure faster than we are funding care for the people the same drug has already hurt.

The National Institute of Mental Health opened a $20 million funding opportunity for a research network on rapid-acting psychiatric drugs, including ketamine, its nasal cousin esketamine, and psilocybin, announced alongside ibogaine research awards. Awards are expected in summer 2027. That is good science policy. These drugs earned the “rapid-acting” label because they can move severe depression faster than standard antidepressants, and psychiatry needs better data on who they help and how long it lasts. We have written about ketamine’s two lives, clinic and street, and both are real.

The Harding survey is the other life. About 60% of respondents reported bladder problems, the scarring damage doctors call ketamine uropathy, and 56% reported “K-cramps,” severe abdominal pain. Most who had physical symptoms never sought care; of those who did, only 36% were satisfied with it. The biggest reason people stayed away was not cost. It was shame: 42% of those not seeking treatment named fear of judgement, and one said plainly, “I was never honest about why I was experiencing bladder problems because I was too embarrassed.” The study has limits worth naming: it is a self-selected online sample, mostly from the UK, recruited partly through Reddit, so it tells us what treatment feels like from the inside, not how common these harms are. And the medication evidence for treating ketamine use disorder is still mostly case reports.

If you are the person hiding the bladder pain, you are not the first, and the pain is not something to wait out. Tell the urologist or ER what you have been using. It changes what they look for.

For clinicians, the step this week costs nothing: when a young adult presents with urinary urgency, pain, or blood in the urine and no infection, ask about ketamine directly. And retire “just stop” as a treatment plan. Nobody in that survey needed to be told to stop. They needed someone who believed it was hard.

The new network should include a use-disorder arm. A medicine strong enough to move depression that fast is strong enough to deserve a plan for the people it takes something from.

Filed Under

policypsychologytreatmentKetamineStigmaThe Treatment GapPeer-Reviewed ResearchFederalFunding

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section